Showing Results for
- Academic Journals (293)
Search Results
- 293
Academic Journals
- 293
-
From:Indian Journal of Medical and Paediatric Oncology (Vol. 34, Issue 1) Peer-ReviewedByline: Swaroop. Revannasiddaiah, Madhup. Rastogi, Manoj. Gupta, Rajeev. Seam Sir, Having read the article titled, "Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized...
-
From:Future Oncology (Vol. 11, Issue 14) Peer-ReviewedAuthor(s): Alexandre Chan aff1 aff2 , Mingjun Song aff3 , Mark Ryan De Guzman Langit aff1 , Teh Aun Lim aff4 , Warren Fong aff5 , Kevin Tay aff3 , Soon Thye Lim aff3 , Tiffany Tang [*] aff3 KEYWORDS carotid...
-
From:Reactions Weekly (Issue 1312)[S] A 70-year-old man developed interstitial pneumonitis during gemcitabine therapy for bile duct cancer. The man, who had undergone pancreaticoduodenectomy in August 2007 for stage I lower bile duct cancer,...
-
From:Reactions Weekly (Issue 1316)[*] In a study involving 16 patients (aged 24--80 years; eight men and eight women), four patients developed drugassociated linear IgA bullous dermatosis (LABD). The patients experienced LABD during treatment with...
-
From:Expert Review of Anticancer Therapy (Vol. 9, Issue 10) Peer-ReviewedAuthor(s): Raphaël Maréchal 1 , Jean-Luc Van Laethem [[dagger]] 2 Keywords: deoxycytidine kinase; gemcitabine; Hu antigen R; pancreatic adenocarcinoma Gemcitabine, a 2´2´-difluoro-2´-deoxycytidine analog, is...
-
From:Future Oncology (Vol. 1, Issue 1) Peer-ReviewedAuthor(s): L Toschi 1 , G Finocchiaro 2 , S Bartolini 3 , V Gioia 4 , F Cappuzzo [[dagger]] 5 Keywords: cancer; chemotherapy; gemcitabine During the last few years, several new chemotherapy compounds have...
-
From:PLoS ONE (Vol. 7, Issue 12) Peer-ReviewedAuthor(s): Ozan Kahramanogullari 1 , * , Gianluca Fantaccini 1 , Paola Lecca 1 , Daniele Morpurgo 1 , Corrado Priami 1 , 2 Introduction Gemcitabine (2,2-difluorodeoxycytidine, dFdC) is a prodrug, which is commonly...
-
From:International Archives of Medicine (Vol. 2, Issue 7) Peer-ReviewedAuthors: Doaa W Maximous [1]; Mostafa E Abdel-Wanis [2]; Mohammed I El-Sayed [2]; Alaa A Abd-Elsayed (corresponding author) [3] Introduction Almost 30% of patients with pancreatic cancer have locally advanced...
-
From:PLoS ONE (Vol. 6, Issue 6) Peer-ReviewedSurvival rates for patients with pancreatic cancer are extremely poor due to its asymptomatic progression to advanced and metastatic stage for which current therapies remain largely ineffective. Therefore, novel...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 29) Peer-ReviewedBackground The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been shown to be a promising regimen for patients with unresectable pancreatic cancer. Methods Six patients...
-
From:PLoS ONE (Vol. 10, Issue 7) Peer-ReviewedPreclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to...
-
From:PLoS ONE (Vol. 14, Issue 10) Peer-ReviewedPurpose Development of a supervised machine-learning model capable of predicting clinically relevant molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) from diffusion-weighted-imaging-derived radiomic...
-
From:Reactions Weekly (Issue 1245)[S] A 60-year-old woman developed acute coronary syndrome while receiving gemcitabine for metastatic leiomyosarcoma. Following admission for bilateral pulmonary nodules at aged 59 years, the woman experienced...
-
From:Advances in Oncology (Vol. 5, Issue 4) Peer-ReviewedCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer Valle J, Wasan H, Palmer DH et al N Engl J Med, 2010, 362, 1273-1281 The majority of biliary tract cancers (BTCs) are diagnosed at an...
-
From:Reactions Weekly (Issue 1284)[S] A 59-year-old man with pancreatic cancer developed toxic erythema during adjuvant chemotherapy with gemcitabine [outcome not clearly stated]. The man underwent pancreatectomy, splenectomy and partial...
-
From:Thorax (Vol. 57, Issue 1) Peer-ReviewedBackground: Lung cancer remains a devastating disease with few effective treatment options. Recent developments in chemotherapy have led to cautious optimism. This paper reviews the evidence an the clinical and cost...
-
From:Pharmacogenomics (Vol. 13, Issue 9) Peer-ReviewedAuthor(s): Hye In Woo 1 , Ka-Kyung Kim 1 2 , Hangseok Choi 3 , Seonwoo Kim 3 , Kee-Taek Jang 4 , Jun Ho Yi 5 , Young Suk Park 5 , Joon Oh Park [*] 7 , Soo-Youn Lee [*] 6 KEYWORDS : CMPK1; gemcitabine;...
-
From:Future Oncology (Vol. 4, Issue 1) Peer-ReviewedAuthor(s): Stefan Boeck [[dagger]] 1 , Volker Heinemann 2 Keywords: chemotherapy; gemcitabine; pancreatic cancer; refractory; second-line; treatment failure Unresectable pancreatic adenocarcinoma remains a...
-
From:Reactions Weekly (Issue 1335)[S] Two 73-year-old women with adenocarcinoma developed injection site reactions during treatment with WT1 peptide loaded dendritic cell vaccine and gemcitabine as part of a phase I clinical trial [time to reaction...
-
From:PLoS ONE (Vol. 10, Issue 7) Peer-ReviewedRelapsed, refractory lymphoma remains to be a challenge and lacks efficient treatment. Some tumor cells escape from treatment, become resistant to chemotherapeutic agents, and rapidly regenerate into large tumors....